MERU is a Phase 3, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy of rovalpituzumab tesirine (Rova-T) as maintenance therapy following first-line, platinum-based chemotherapy in small-cell lung cancer (
SCLC).
The application will be based on data from the
SCLC cohort of the lurbinectedin Phase II monotherapy basket trial that enrolled a total of 105 patients at 39 centres in over nine countries in Western Europe and the United States.
Lung cancer is the leading cause of cancer death globally.2 Each year 1.76 million people die as a result of the disease; this translates into more than 4,800 deaths worldwide every day.2 Lung cancer can be broadly divided into two major types: NSCLC and
SCLC, with
SCLC accounting for approximately 15% of all lung cancer cases.3 About Tecentriq (atezolizumab)
Reportedly, in June 2019, the phase III CASPIAN trial met its primary endpoint with Imfinzi by showing a statistically-significant and clinically-meaningful improvement in overall survival for patients with extensive-stage
SCLC. These patients were treated with Imfinzi in combination with standard-of-care etoposide and platinum-based chemotherapy vs.
That protein is found in more than 80 percent of small-cell lung cancer (
SCLC) patient tumors.
The research, published in Cancer Discovery, suggest that the PARP inhibitor olaparib and other DDR inhibitors induce a rapid immune response and sensitise
SCLC cells to immunotherapy, to which they were previously resistant.
SCLC, an extremely aggressive form of lung cancer, is found mostly in smokers and usually becomes resistant within several months to existing treatments, such as chemo- and radiotherapy.
Ernesto Torres Jr., the commander of 1003rd Infantry Brigade, said they are collating evidence to prove the link of
SCLC to the Communist movement.
A CT-guided percutaneous transthoracic needle biopsy (PTNB) was performed (Sample B), showing a combined tumor presenting adenocarcinoma and
SCLC features with the original EGFR ex19del.
To characterise this minority of cells, the research team used a method they developed that employs the gene-editing tool CRISPR to screen for specific proteins that are critical to the growth of various human cancer cell lines, including
SCLC lines.